Table 6. Summary of methotrexate associated lymphoproliferative disorders (MTX-LPDs).
| MTX-LPD | N | Female (%) | Age* (y) | Basal disease* (y) | MTX duration* (y) | CS 3 or 4 |
EBV+ (%) |
Clinical course (%) | Survival rate (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R-G | R/R-G | P-G | Ch-G | All | R-G | R/R-G | P-G | Ch-G | |||||||||
| EBV+DLBCL | 66 | 71 | 68 | 13.5 | 6.1 | 62 | 100 | 62 | 3 | 17 | 17 | 91 | 95 | 100 | 72 | 90 | |
| DLBCL-NOS | 50 | 59 | 66 | 11.1 | 5.4 | 60 | 0 | 26 | 6 | 36 | 26 | 60 | 100 | 67 | 72 | 53 | |
| CHL | 51 | 74 | 62 | 13 | 5.6 | 75 | 76 | 14 | 40 | 24 | 21 | 78 | 100 | 65 | 67 | 100 | |
| P-LPD | 17 | 64 | 65 | 11 | 7.2 | 64 | 100 | 76 | 18 | 0 | 6 | 82 | 92 | 33 | - | 0 | |
| EBVMUCU | 32 | 84 | 70 | 9.4 | 6.3 | -** | 100 | 81 | 3 | 13 | 3 | 97 | 100 | 100 | 75 | 100 | |
| NS-LPD | 9 | 56 | 65 | 16 | 8.9 | 33 | 57 | 89 | 11 | 0 | 0 | 89 | 100 | 0 | - | - | |
| Total | 225 | 70 | 66 | 12.5 | 6.1 | 54.7 | 70.6 | 48 | 13.5 | 20.3 | 16.4 | 81.3 | 97.2 | 67.7 | 67.2 | 81 | |
EBV, Epstein-Barr virus; DLBCL, diffuse large B cell lymphoma; NOS, not otherwise specified; CHL, classical Hodgkin lymphoma; P-LPD, polymorphic LPD; EBVMCU, EEBV-positive mucocutaneous ulcer; CS, clinical stage; R-G, regression group; R/R-G, relapse/regrowth group; P-G, persistent group; Ch-G, chemotherapy group.
* indicated mean values. ** involved sites were mainly oral cavity and/or skin.